OBJECTIVES: To determine the efficacy and safety of eplerenone therapy in children with hypertension. STUDY DESIGN: A total of 304 children age 4-16 years with systolic blood pressure (SBP) >or=95th percentile were randomized to low-dose (25 mg daily), middle-dose (25 mg twice daily), or high-dose (50 mg twice daily) eplerenone (phase A), then rerandomized to active therapy or placebo for another 4 weeks (phase B). The primary endpoint was change in SBP in phase B. RESULTS: During phase A, mean SBP decreased from baseline by 8 mm Hg, and diastolic blood pressure (DBP) decreased by up to 3.8 mm Hg; no dose-response relationship was demonstrated. Mean differences in SBP from placebo during phase B were -2.61 for the low-dose group, +2.32 for the middle-dose group, and -2.76 mm Hg for the high-dose group; only the reduction in the high-dose group was statistically significant (P = .048). No significant effects on DBP of eplerenone therapy relative to placebo were detected. Eplerenone was well tolerated, with a rate of adverse events comparable to that of placebo. CONCLUSIONS: Short-term treatment with eplerenone reduced blood pressure in children with hypertension and had acceptable tolerability. Copyright (c) 2010 Mosby, Inc. All rights reserved.
RCT Entities:
OBJECTIVES: To determine the efficacy and safety of eplerenone therapy in children with hypertension. STUDY DESIGN: A total of 304 children age 4-16 years with systolic blood pressure (SBP) >or=95th percentile were randomized to low-dose (25 mg daily), middle-dose (25 mg twice daily), or high-dose (50 mg twice daily) eplerenone (phase A), then rerandomized to active therapy or placebo for another 4 weeks (phase B). The primary endpoint was change in SBP in phase B. RESULTS: During phase A, mean SBP decreased from baseline by 8 mm Hg, and diastolic blood pressure (DBP) decreased by up to 3.8 mm Hg; no dose-response relationship was demonstrated. Mean differences in SBP from placebo during phase B were -2.61 for the low-dose group, +2.32 for the middle-dose group, and -2.76 mm Hg for the high-dose group; only the reduction in the high-dose group was statistically significant (P = .048). No significant effects on DBP of eplerenone therapy relative to placebo were detected. Eplerenone was well tolerated, with a rate of adverse events comparable to that of placebo. CONCLUSIONS: Short-term treatment with eplerenone reduced blood pressure in children with hypertension and had acceptable tolerability. Copyright (c) 2010 Mosby, Inc. All rights reserved.
Authors: Perdita Taylor-Zapata; Carissa M Baker-Smith; Gilbert Burckart; Stephen R Daniels; Joseph T Flynn; George Giacoia; Dionna Green; Aaron S Kelly; Mona Khurana; Jennifer S Li; Charlotte Pratt; Elaine M Urbina; Anne Zajicek Journal: Pediatrics Date: 2019-05 Impact factor: 7.124
Authors: Tina Sc Tam; May Hy Wu; Sarah C Masson; Matthew P Tsang; Sarah N Stabler; Angus Kinkade; Anthony Tung; Aaron M Tejani Journal: Cochrane Database Syst Rev Date: 2017-02-28
Authors: Kan N Hor; Michael D Taylor; Hussein R Al-Khalidi; Linda H Cripe; Subha V Raman; John L Jefferies; Robert O'Donnell; D Woodrow Benson; Wojciech Mazur Journal: J Cardiovasc Magn Reson Date: 2013-12-21 Impact factor: 5.364
Authors: Subha V Raman; Kan N Hor; Wojciech Mazur; Xin He; John T Kissel; Suzanne Smart; Beth McCarthy; Sharon L Roble; Linda H Cripe Journal: Orphanet J Rare Dis Date: 2017-02-20 Impact factor: 4.303